Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
- 4 November 2009
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 21 (5), 936-941
- https://doi.org/10.1093/annonc/mdp466
Abstract
Background: In metastatic renal cell carcinoma (mRCC), antiangiogenic treatments rarely achieve a reduction of −30% in the sum of longest diameters (SLD) of target lesions required by RECIST for an ‘objective response’, although they objectively improve progression-free survival (PFS). We sought to determine a threshold for the computed tomography evaluation of these patients’ best reflecting patient outcome. Patients and methods: In 334 mRCC patients treated with sunitinib, we tested thresholds from −45% to +10%. We classified patients as ‘responders’ when the best relative variation of the sum of longest diameters (ΔSLD) reached the tested threshold and as ‘nonresponders’ otherwise. For each tested threshold, the median PFS of the two groups were compared. Receiver operating characteristic (ROC) analysis was also carried out among the 103 patients that progressed during follow-up. Finally, the ‘optimal’ threshold was retested on an independent cohort of 39 patients. Results: The ΔSLD threshold of −10% gave the most significant difference. It divided patients into 256 responders and 78 nonresponders (median PFS 11.1 and 5.6 months). The same −10% threshold was found using the ROC analysis. Results were confirmed on the external validation cohort. Conclusion: A variation of −10% in the SLD accurately and rapidly identifies mRCC patients benefiting from sunitinib.This publication has 21 references indexed in Scilit:
- Validation of novel imaging methodologies for use as cancer clinical trial end-pointsEuropean Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Evaluation of lymph nodes with RECIST 1.1European Journal of Cancer, 2009
- Treatment options in renal cell carcinoma: past, present and futureAnnals of Oncology, 2007
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Imaging Tumour AngiogenesisCancer Imaging, 2005
- Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTJournal of Clinical Oncology, 2004
- Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor ResponseJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000